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Cardiotrophin-1 (CT-1) was recently isolated by ex-
pression cloning based on its ability to induce an in-
crease in cell size in neonatal rat ventricular cardio-
myocytes. Sequence similarity data suggested that CT-1
is a novel member of a family of structurally related
cytokines sharing the receptor component gp130. The
present study documents that gp130 is required for CT-1
signaling in cardiomyocytes, by demonstrating that a
monoclonal anti-gp130 antibody completely inhibits c-
fos induction by CT-1. Similarly, a leukemia inhibitory
factor receptor subunit b (LIFRb) antagonist effectively
blocks the CT-1 induction of c-fos, indicating a require-
ment for LIFRb in the hypertrophic response, as well.
Upon stimulation with CT-1, both gp130 and the LIFRb
are tyrosine-phosphorylated, providing further evi-
dence that CT-1 signals through the gp130/LIFRb het-
erodimer in cardiomyocytes. CT-1 induces a hyper-
trophic response in cardiomyocytes that is distinct from
the phenotype seen after a-adrenergic stimulation, both
with regard to cell morphology and gene expression
pattern. Stimulation with CT-1 results in an increase in
cardiac cell size that is characterized by an increase in
cell length but no significant change in cell width. Con-
focal laser microscopy of CT-1 stimulated cells reveals
the assembly of sarcomeric units in series rather than in
parallel, as seen after a-adrenergic stimulation. CT-1
induces a distinct pattern of immediate early genes, and
up-regulates the atrial natriuretic factor (ANF) gene,
but does not affect skeletal a-actin or myosin light
chain-2v expression. As evidenced by nuclear run-on
transcription assays, both CT-1 and a-adrenergic stimu-
lation lead to an increase in ANF gene transcription.
Transient transfection analyses document that, in con-
trast to a-adrenergic stimulation, the CT-1 responsive
cis-regulatory elements are located outside of the prox-
imal 3 kilobase pairs of the ANF 5*-flanking region.
These studies indicate that CT-1 can activate a distinct
form of myocardial cell hypertrophy, characterized by
the promotion of sarcomere assembly in series, via
gp130/LIFRb-dependent signaling pathways.
Hypertrophy is one of the most important compensatory
responses of the myocardium, as it is critical for the mainte-
nance of normal cardiac function in response to pressure over-
load in the setting of hypertension or volume overload during
valvular insufficiency. However, the mechanical stimuli of
pressure versus volume overload produce distinct cardiac mus-
cle phenotypes, with the former resulting in a concentric pat-
tern of hypertrophy, and the latter promoting an eccentric form
of hypertrophy with cardiac chamber dilation. On a single cell
level, cardiac myocytes isolated from concentric hypertrophic
hearts display an increase in cell diameter with the addition of
new myofibrils in parallel (1, 2), while myocytes derived from
dilated hearts exhibit an increase in cell length, reflecting the
addition of new sarcomeric units in series (3, 4). These distinct
morphological phenotypes are associated with different effects
on global cardiac function. Chronic volume overload hypertro-
phy can result in an irreversible loss of cardiac function, while
pressure overload hypertrophy is usually associated with the
preservation of contractile function, and can often be reversi-
ble. While both forms of hypertrophy can lead to the induction
of the atrial natriuretic factor gene, distinct molecular pheno-
types have also recently been observed (5). Although it has long
been accepted that there are distinct morphologic forms of
hypertrophy in the setting of pressure or volume overload, the
signaling pathways which mediate these distinct cardiac phe-
notypes remain unclear. One of the critical questions is
whether divergent signaling pathways are responsible for the
activation of these distinct forms of hypertrophy that display
clear differences with respect to cell morphology, physiology,
and the induction of molecular markers.
Our current insight into the mechanisms controlling car-
diomyocyte hypertrophy has primarily been obtained from an
in vitro model employing neonatal rat ventricular myocytes. A
number of growth factors signaling through G-protein coupled
receptors, including a-adrenergic agonists (6–11), endothelin 1
(12, 13), and angiotensin II (14), promote a hypertrophic re-
sponse in this in vitro system. Following activation of the
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G-protein-dependent pathways, cardiomyocytes display a uni-
form enlargement of cell size, with increases in cell width and
length, resulting from the assembly of new myofibrils in par-
allel (12, 15, 16). ras-dependent pathways appear to be both
necessary and sufficient to activate the hypertrophic response
following a-adrenergic stimulation in the in vitromodel system
(17), and a recent study in transgenic mice documented that
the overexpression of a constitutively active ras protein in the
ventricular chambers results in a concentric form of cardiac
hypertrophy (18). Taken together, these studies indicate that
G-protein coupled receptors and ras-dependent pathways acti-
vate a form of cardiac hypertrophy that resembles the hyper-
trophy seen in the setting of pressure overload. The question
arises as to whether divergent signaling pathways would me-
diate a volume overload like hypertrophic phenotype, charac-
terized by sarcomere assembly in series and myocyte enlarge-
ment primarily due to an increase in cell length versus width.
By coupling expression cloning to a miniaturized version of
the in vitro hypertrophy assay, we have recently isolated a
novel 21.5-kDa protein that induces an increase in cell size and
atrial natriuretic factor (ANF)1 release in cardiomyocytes (19).
The protein was designated cardiotrophin-1 (CT-1). Sequence
similarity data and structural considerations suggest that
CT-1 is a new member of a family of structurally related cyto-
kines including interleukin (IL)-6 and IL-11, leukemia-inhibi-
tory factor (LIF), ciliary neurotrophic factor (CNTF), and on-
costatin M (OSM). The receptors of this cytokine family are
multimeric and share the class-specific transmembrane signal
transducing component gp130 (20–23). Signaling is triggered
through the homodimerization of gp130 (24), or the het-
erodimerization of gp130 with a related transmembrane signal
transducer, the LIF receptor subunit b (LIFRb (25, 26). The
gp130/LIFRb heterodimer constitutes the functional bipartite
LIF receptor complex (22, 27). Other members of this cytokine
family first bind to a private receptor component and subse-
quently induce gp130 dimerization. For example, IL-6 binds to
the receptor component IL-6R, and the IL-6zIL-6R complex
then induces the homodimerization of gp130 (28, 29); CNTF
binds to the receptor component CNTFRa and induces gp130/
LIFRb heterodimerization (26, 30, 31). Consequently, the ex-
pression pattern of the various receptor components defines the
spectrum of action of different members of the gp130 cytokine
family.
The cloning of CT-1 based on its ability to induce an increase
in cell size in cardiomyocyte culture (19) suggested that gp130-
dependent signaling pathways may be coupled to cardiomyo-
cyte hypertrophy. In the present study we define the receptor
system used by CT-1 in cardiomyocytes, and we examine the
effects of CT-1 and two other members of the IL-6 cytokine
family, LIF and CNTF, on morphological and molecular fea-
tures defining a hypertrophic response in cultured cardiomyo-
cytes. By using a monoclonal anti-gp130 antibody and a LIFRb
antagonist, we establish that both gp130 and LIFRb are re-
quired for CT-1 signaling in cardiomyocytes. Immunoprecipi-
tation and immunoblotting data show that CT-1 induces the
tyrosine phosphorylation of gp130 and a higher molecular
weight protein, corresponding in size to LIFRb. Using confocal
laser microscopy of cells stained for both thick and thin fila-
ment markers, our studies further indicate that gp130/LIFRb-
dependent signaling pathways induce a hypertrophic pheno-
type in cardiomyocytes that is distinct from the response seen
after a-adrenergic stimulation, and that shows resemblance to
volume overload cardiac hypertrophy both with regard to cell
morphology and gene expression pattern.
EXPERIMENTAL PROCEDURES
Murine LIF was produced at Genentech, Inc. Murine LIF was used
throughout the study, except for the experiment employing the LIFRb
antagonist (hLIF-04), in which both murine LIF and human LIF were
used. Rat CNTF and human IL-6 were purchased from Boehringer
Mannheim and from Genzyme, respectively. Human sIL-6R was pre-
pared as outlined previously (21). The a-adrenergic agonist phenyleph-
rine (PE) was obtained from Sigma.
Expression and Purification of the CT-1 Fusion Protein—The reading
frame of murine CT-1 was cloned C-terminal to the sequence encoding
the herpes simplex virus glycoprotein D followed by a factor Xa cleavage
site. Following expression in 293 cells and cleavage of the herpes sim-
plex virus secretion signal sequence, the CT-1 fusion protein contained
a 34-amino acid N-terminal extension followed by the CT-1 sequence
(19). The CT-1 fusion protein was purified from conditioned medium
with a herpes simplex virus glycoprotein D-specific monoclonal anti-
body and quantified by a colorimetric assay (Bio-Rad).
LIFRb Antagonist hLIF-04—The LIFRb antagonist hLIF-04 was
used to assess the requirement of the LIFRb for CT-1 signaling. Human
LIF (hLIF) and the hLIF mutant, hLIF-04, were expressed as glutathi-
one S-transferase fusion proteins, as described previously (32). hLIF-04
contains three amino acid substitutions (Q25A, S28A, and Q32A),
within the A-helix of the hLIF molecule, resulting in a selective disrup-
tion of the gp130 binding site, but no impairment in LIFRb binding. A
detailed characterization of the LIFRb antagonist hLIF-04 will be pre-
sented elsewhere.2
Cell Culture—Hearts from 1–3-day-old Sprague-Dawley rats were
removed, the ventricles were pooled, and the ventricular cells were
dispersed by digestion with collagenase II (Worthington) and pancrea-
tin (Life Technologies, Inc.). The cell suspension was purified by cen-
trifugation through a discontinuous Percoll gradient to obtain myocar-
dial cell cultures with .95% myocytes, as assessed by immunofluores-
cence with an anti-TrpE/MLC-2v antiserum (12, 33). The cardiomyo-
cytes were plated at a density of 5–6 3 104 cells/cm2 in Dulbecco’s
modified Eagle’s medium (DMEM)/medium 199 (4:1) supplemented
with 10% horse serum, 5% fetal bovine serum, glutamine and antibiot-
ics (plating medium), and allowed to attach overnight. The cells were
then washed twice with DMEM/medium 199 and further incubated in
DMEM/medium 199 supplemented with glutamine and antibiotics
(maintenance medium) in the presence or absence of various agents.
Neonatal mouse ventricular myocytes were isolated from 1–4-day-old
NIH Swiss mice, following the protocol outlined above. One litter (8–12
pups) yielded ;5 3 105 cells. Approximately 95% of the cells displayed
spontaneous contractile activity in culture.
Immunoprecipitation and Immunoblotting—Cardiomyocytes were
stimulated with various agents and solubilized with ice cold lysis buffer
(0.5% Nonidet P-40, 150 mM NaCl, 10 mM Tris-HCl, pH 8.0, 5 mM
EDTA, 2 mM sodium vanadate, 1 mM p-amidinophenylmethanesulfonyl
fluoride (Sigma), 5 mg/ml aprotinin). Clear lysates were obtained by
centrifugation and immunoprecipitated with a polyclonal rabbit anti-
gp130 cytoplasmic peptide antibody (34). Immunoprecipitates (protein
A-Sepharose, Pharmacia Biotech Inc.) were subjected to SDS-PAGE
under reducing conditions and immunoblotted with an anti-phosphoty-
rosine antibody (4G10, Upstate Biotechnology), employing an enhanced
chemiluminescence detection system (Amersham Corp.). For the detec-
tion of protein tyrosine phosphorylation, the cell lysates were analyzed
directly by SDS-PAGE and immunoblotting with 4G10.
Immunofluorescence Techniques and Morphometric Analysis—Car-
diomyocytes were plated in Lab-Tek plastic chamber slides (Nunc),
precoated with 4 mg/cm2 laminin (Sigma), and incubated in the presence
or absence of various agents. After 48 h, the cells were rinsed with
phosphate-buffered saline, fixed in 4% paraformaldehyde, and perme-
abilized with 0.3% Triton X-100. Following three phosphate-buffered
saline washes, the chamber slides were incubated in 3% bovine serum
albumin for 10 min to block nonspecific sites. Subsequently, the cells
1 The abbreviations used are: ANF, atrial natriuretic factor; CT-1,
cardiotrophin-1; LIF, leukemia inhibitory factor; hLIF, human LIF; IL,
interleukin; CNTF, ciliary neurotrophic factor; CNTFR, CNTF receptor;
OSM, oncostatin M; PE, phenylephrine; (s)IL-6R, (soluble) IL-6 recep-
tor; LIFRb, LIF receptor subunit b; MLC-2v, ventricular myosin light
chain-2; bMHC, b myosin heavy chain; GAPDH, glyceraldehyde-3-
phosphate dehydrogenase; DMEM, Dulbecco’s modified Eagle’s me-
dium; Tricine, N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]glycine; I.E.,
immediate early; PAGE, polyacrylamide gel electrophoresis; RSV, Rous
sarcoma virus; bp, base pair(s); kb, kilobase pair(s).
2 K. R. Hudson, A. B. Vernallis, and J. K. Heath, manuscript submit-
ted for publication.
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were dual-stained for 1 h in 3% bovine serum albumin with 1) a
polyclonal anti-TrpE/MLC-2v antiserum from rabbit (12), combined
with a monoclonal mouse anti-rat ANF antibody (35, 36), or 2) a mono-
clonal mouse anti-human b myosin heavy chain (bMHC) antibody (37),
combined with rhodamine phalloidine (Molecular Probes). Following
four phosphate-buffered saline washes, the slides were blocked with 5%
normal donkey serum for 10 min, incubated for 1 h in 5% normal
donkey serum using a Texas Red-conjugated donkey anti-rabbit IgG
and a fluorescein isothiocyanate-conjugated donkey anti-mouse IgG as
secondary antibodies (Jackson Laboratories), and finally mounted on
glass coverslips. Cardiomyocytes stained against MLC-2v and ANF
were viewed by fluorescence microscopy. Cell size was estimated by
measuring the area to which individual MLC-2v-positive cells attached
(planimetry), cell length and width were determined as outlined in Fig.
1, and the percentage of MLC-2v positive cells that displayed perinu-
clear staining for immunoreactive ANF was calculated. Cardiomyocytes
stained against bMHC and F-actin (rhodamine phalloidine) were ana-
lyzed by confocal laser microscopy using a 60 3 oil immersion objective.
Images of cardiomyocytes stained against bMHC were used to deter-
mine the effect of various agonists on the average sarcomere length.
ANF Radioimmunoassay—The concentration of immunoreactive
ANF in cell culture supernatants was determined by radioimmunoas-
say, using the monoclonal mouse anti-rat ANF antibody with synthetic
ANF-(99-126) as the standard and 125I-ANF-(99-126) (Amersham) as
the trace (35).
Isolation and Hybridization of RNA—Total cellular RNA was iso-
lated by a modification of the acid guanidium/thiocyanate phenol/chlo-
roform extraction method (38) using the RNA STAT 60 RNA isolation
reagent (Tel-Test “B”). RNA was size-fractionated by formaldehyde
agarose gel electrophoresis, transferred to nylon filters (Magna NT) by
overnight capillary blotting, and hybridized with cDNA probes labeled
with [a-32P]dCTP by random priming (Life Technologies, Inc.). The
filters were washed under stringent conditions and exposed to x-ray
film (Kodak X-Omat AR). Signal intensities were determined by densi-
tometry (UltroScan XL, Pharmacia). The following cDNA probes were
used: mouse c-fos (1.2-kb fragment) (39), mouse egr-1 (zif/268) (1.7-kb
fragment (40), human c-myc (1.6-kb fragment, a generous gift of Dr. J.
Feramisco), mouse c-jun (2.6-kb fragment) (41), mouse jun-B (1.90-kb
fragment) (42), mouse tis11 (1.0-kb fragment, a generous gift of Dr. H.
R. Herschman) (43), rat prepro-ANF (0.6 kb of coding region) (44), rat
skeletal a-actin (0.2 kb of a 39-untranslated region generated by reverse
transcriptase-polymerase chain reaction from skeletal muscle poly(A)1
RNA) (45) and rat MLC-2v (0.6 kb of coding region) (46). Human
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (1.2-kb frag-
ment) (47) and mouse 28s (5-kb fragment) cDNA probes were used to
control for loading and transfer efficiency.
Nuclear Run-on Transcription Assay—Run-on transcription assays
were performed as described previously (48). Cardiomyocytes were ly-
sed in ice-cold Nonidet P-40 buffer (10 mM Tris-HCl, pH 7.5, 10 mM
NaCl, 3 mM MgCl2, 0.5% Nonidet P-40) and further disrupted by 10
gentle strokes with a loose pestle in a Dounce homogenizer. The nuclei
were recovered by centrifugation. The supernatants (representing the
cytosolic fractions) were saved, and vanadylribonucleoside complexes
(Life Technologies, Inc.) were added to inhibit RNase activity. Total
RNA was isolated from the cytosolic fractions and subjected to Northern
blot analysis using prepro-ANF, GAPDH, and 28s cDNA probes. The
nuclei were washed once in Nonidet P-40 buffer, resuspended in 100 ml
of storage solution (50% glycerol, 50 mM HEPES, pH 7.4, 5 mM MgCl2,
0.1 mM EDTA, 5 mM dithiothreitol), and stored at 280 °C. On the day of
the assay, the nuclei were thawed, 27.5 ml of run-on buffer (25 mM
Tris-HCl, pH 7.5, 12.5 mM MgCl2, 750 mM KCl, 25 mM dithiothreitol,
1.25 mM of ATP, GTP, and CTP), 6 ml (62.5 mCi) of [a-32P]UTP, and 1 ml
of RNasin (Promega) were added, and the nuclei were incubated at
30 °C for 30 min. Following DNA and protein digestion (RQ-1 DNase 1,
Promega; proteinase K, Life Technologies, Inc.), the 32P-labeled RNA
was extracted once with phenol/chloroform, ethanol-precipitated, and
purified over a RNase-free Sephadex G50 column (Boehringer Mann-
heim). The total amount of 32P-labeled RNA recovered from each reac-
tion was determined by liquid scintillation counting (Beckman). Five
micrograms of linearized, alkali-denatured pBluescript (Stratagene),
pBluescript harboring the rat prepro-ANF cDNA (44), and pBluescript
harboring the human GAPDH cDNA (47) were spotted onto nylon
filters in advance. The filters were prehybridized for 1 h in 56.25%
formamide, 0.25 M sodium phosphate, pH 7.2, 0.25 M NaCl, 1 mM EDTA,
7% SDS. An equal number of counts from each run-on reaction were
added to the prehybridization solution, and hybridizations were carried
out for 48 h at 42 °C. Finally, the filters were washed under stringent
conditions and exposed to x-ray film. The amount of ANF and GAPDH-
specific hybridization was determined by densitometry. No hybridiza-
tion to the empty pBluescript control was detectable (data not shown).
Plasmid Constructs—pANF(23003)Luc59, an ANF-luciferase re-
porter construct composed of the most proximal 3003 bp of the rat ANF
gene 59-flanking region inserted into the promoterless firefly luciferase
reporter plasmid pSVOALuc59 was used to assess the CT-1-, LIF-,
CNTF-, and PE-induced activity of the rat ANF promoter (11). pRSV-
Luc59, a RSV-luciferase reporter construct, and pSVOALuc59 served as
positive and negative controls, respectively (49). To correct for trans-
fection efficiency, cardiomyocytes were cotransfected with pON249, a
b-galactosidase expression vector under the control of the human cyto-
megalovirus promoter (50).
Transfection and Luciferase/b-Galactosidase Assays—Cells were
plated in 3.5-cm dishes in duplicate, allowed to attach overnight, and
switched to maintenance medium supplemented with 4% horse serum.
Two hours later, the cells were cotransfected with 2.75 mg of either
pANF(23003)Luc59, pRSVLuc59, or pSVOALuc59, and 0.75 mg of
pON249 using the calcium phosphate method as described by Chen and
Okayama (51). After 18–20 h, the cells were washed twice to remove the
fine layer of calcium precipitate and incubated in maintenance medium
in the presence or absence of various agents. At different time points,
the cells were washed twice with ice-cold phosphate-buffered saline and
were lysed for 30 min on ice in 100 ml of lysis buffer (0.1 M KH2PO4, pH
7.9, 0.5% Triton X-100, 1 mM dithiothreitol). Luciferase activities were
determined in duplicate samples from each plate; 20 ml of cell lysate
were combined with 100 ml of luciferase assay buffer (100 mM Tricine,
pH 7.8, 10 mM MgSO4, 2 mM EDTA, 2 mM ATP, 1 mM dithiothreitol, 73
mM b-luciferin), and luciferase activities were measured using a Mono-
light 401 luminometer (Analytical Luminescence Laboratory). b-Galac-
tosidase activities were determined in duplicate samples from each
plate; 20 ml of cell lysate were added to 250 ml of b-galactosidase assay
buffer (0.1 M sodium phosphate, pH 7.3, 1.2 mM MgCl2, 60 mM b-mer-
captoethanol, 1.8 mM chlorophenol red-b-D-galactopyranoside (Boeh-
ringer Mannheim)), and incubated at 37 °C for 15 min. b-Galactosidase
activities were obtained by measuring OD at 574 nm, using lysis buffer
as a blank.
Statistical Analysis—Data are presented as means 6 S.E. p values
were determined using one-way analysis of variance.
RESULTS
Induction of a Distinct Pattern of Immediate Early Genes
following CT-1 versus a-Adrenergic Stimulation of Cultured
Myocardial Cells—The induction of immediate early (I.E.)
genes precedes the late phenotypic changes in cardiomyocytes
following the stimulation of G-protein-coupled receptors in
vitro (12–15) and cardiac hypertrophy in vivo (52, 53). We
therefore determined whether stimulation of cardiomyocytes
with CT-1, LIF, or CNTF would induce I.E. gene expression
(Fig. 2). Stimulation with CT-1 resulted in the rapid and tran-
sient induction of a panel of I.E. genes, including c-fos, egr-1,
c-myc, c-jun, jun-B, and tis11. The pattern of I.E. gene expres-
sion in response to stimulation with LIF was virtually indis-
tinguishable from the pattern induced by CT-1. CNTF dis-
played a relatively weak induction of the same panel of I.E.
genes as did CT-1 and LIF. As compared to stimulation with
PE, CT-1, and LIF induced .10 fold higher levels of c-myc and
tis11.
FIG. 1. Definition of morphometric parameters. Cell length was
defined as the maximum longitudinal extension of individual cells.
Maximum cell width was measured perpendicular to the axis defining
cell length.
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Involvement of gp130 and LIFRb in CT-1 Induction of c-fos—
Previous studies have employed blocking antibodies directed
against gp130 to demonstrate that IL-6, LIF, OSM, CNTF, and
IL-11 utilize the common receptor component gp130 (21–23).
Sequence similarity data, as well as structural considerations,
suggest that CT-1 might be a new member of this cytokine
family, and might therefore share the receptor component
gp130 (19). To directly test this hypothesis, we examined the
effect of an anti-gp130 antibody on the CT-1 induction of c-fos
in cardiomyocytes. A monoclonal anti-gp130 antibody (RX435)
was generated by immunizing rats with recombinant murine
gp130.3 RX435 specifically blocks the action of LIF, IL-6, IL-11,
and OSM onmouse myeloid leukemic M1 cells3 and inhibits the
binding of CT-1 to M1 cells (54). Since RX435 does not cross-
react with rat gp130, we used neonatal mouse cardiomyocytes
in this set of experiments. Similar to the rat system, murine
cardiomyocytes responded to stimulation with CT-1, LIF, and
PE with an induction of immediate early genes and typical
morphology changes. However, CT-1, LIF, and PE did not
induce ANF gene expression in murine cardiomyocytes (data
not shown). This might relate to the fact that in mice, in sharp
contrast to rats, the ventricular expression of ANF is not down-
regulated after birth, but instead remains at high levels from
embryogenesis through adulthood (55). We first examined the
effects of different concentrations of CT-1, LIF and PE on the
induction of c-fos in murine cardiomyocytes. CT-1, LIF, and PE
induced c-fos expression in a dose-dependent manner (Fig. 3, A
and B). In subsequent experiments, cardiomyocytes were incu-
bated for 1 h with RX435 or, as a control, with immunopurified
rat IgG prior to stimulation with CT-1, LIF, or PE. RX435 was
used at a concentration that has previously been shown to
inhibit ;80% of CT-1 (0.12 nM) binding to murine M1 cells (54).
CT-1, LIF, and PE were used at concentrations that resulted in
an approximately 4–5-fold induction of c-fos expression. As
shown in Fig. 3, C and D, RX435 completely abolished the
induction of c-fos by CT-1 and LIF. By contrast, the c-fos in-
duction by PE was not abolished by RX435 (although some-
what suppressed), confirming the specificity of the antibody
(Fig. 3D).
To determine whether LIFRb is required for CT-1 signaling,
we studied the effect of a LIFRb antagonist, hLIF-04, on c-fos
induction by CT-1. hLIF-04 was generated by introducing three
amino acid substitutions in the human LIF molecule, thereby
abrogating the gp130 binding site. hLIF-04 has been shown to
antagonize the action of hLIF in a Ba/F3 cell line, stably trans-
fected with human gp130 and LIFRb (see “Experimental Pro-
cedures”). As shown in Fig. 3E, preincubation with hLIF-04
blocked the c-fos induction by human LIF, murine LIF, and by
CT-1. By contrast, c-fos induction by PE was not affected by
hLIF-04. Taken together, the results obtained with the anti-
gp130 blocking antibody and the LIFRb antagonist strongly
suggest that CT-1, like LIF, requires both gp130 and LIFRb to
activate downstream signaling pathways leading to the induc-
tion of c-fos in cardiomyocytes.
CT-1 and LIF Induce Tyrosine Phosphorylation of gp130 and
a 200-kDa Protein in Cardiomyocytes—To examine whether
CT-1 would induce tyrosine phosphorylation of gp130, as it has
been shown for the other members of the IL-6 cytokine family,
cardiomyocytes were stimulated with soluble IL-6R, IL-6, a
combination of IL-6 and sIL-6R, LIF, CT-1, and PE. Cell lysates
were immunoprecipitated with a polyclonal anti-gp130 anti-
serum, analyzed by SDS-PAGE, and immunoblotted with an
anti-phosphotyrosine antibody. As shown in Fig. 4A, the IL-6/
sIL-6R complex, LIF, and CT-1 induced gp130 tyrosine phos-3 M. Saito and T. Taga, unpublished data.
FIG. 2. Immediate early gene induction. Neonatal rat ventricular
cardiomyocytes were plated into 15-cm dishes and serum-starved for 18
h. Thereafter, control cells were harvested; the remaining cells were
stimulated with PE (100 mM), CT-1, LIF, or CNTF (1 nM each), for the
indicated times. Total RNA was isolated and subjected to Northern blot
analysis (10 mg/lane). The following probes were used: c-fos, egr-1,
c-myc, c-jun, jun-B, tis11, and 28s. Data from one experiment are
presented. One additional experiment yielded comparable results.
FIG. 3. Effects of an anti-gp130 antibody and a LIFRb antago-
nist on the c-fos induction by CT-1, LIF, and phenylephrine.
Neonatal mouse ventricular cardiomyocytes were plated into 3.5-cm
dishes and serum-starved for 18 h. Thereafter, the cells were stimu-
lated for 45 min with various concentrations of CT-1, LIF, or PE (Panels
A and B). In a second set of experiments, cells were incubated with a
monoclonal rat anti-mouse gp130 antibody (RX435, 20 mg/ml) or immu-
nopurified rat IgG (20 mg/ml) prior to CT-1 (0.1 nM) stimulation (Panel
C), and LIF (0.1 nM) or PE (100 mM) stimulation (Panel D). In a third
experiment (Panel E), cells were incubated with a LIFRb antagonist
(hLIF-04, 0.5 nM), prior to stimulation with PE (100 mM), human LIF
(hLIF), murine LIF (mLIF), and CT-1 (0.1 nM each). Total RNA was
isolated and subjected to Northern blot analysis (2 mg/lane). Equal
loading and transfer conditions were confirmed by GAPDH and 28s (not
shown) hybridization.
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phorylation. By contrast, no gp130 phosphorylation was detect-
able after stimulation with PE, and with IL-6 or sIL-6R alone.
To compare the pattern of protein tyrosine phosphorylation
induced by the various agonists, cell lysates were subjected to
SDS-PAGE and immunoblotting with the anti-phosphotyrosine
antibody (Fig. 4B). Stimulation with the IL-6/sIL-6R complex,
LIF, and CT-1 resulted in the tyrosine phosphorylation of a
protein, corresponding in size to gp130 (compare to Fig. 4A). An
additional, higher molecular mass protein (approximately 200
kDa) was tyrosine-phosphorylated in response to LIF and CT-1
only, but not in response to the IL-6zsIL-6R complex.
CT-1 Induces a Morphologically Distinct Hypertrophic Re-
sponse Characterized by the Assembly of Sarcomeric Units in
Series—Neonatal rat ventricular cardiomyocytes respond to
various hypertrophic stimuli by an increase in individual cell
size, assembly of myofibrils, and perinuclear accumulation of
ANF. To assess the effects of gp130/LIFRb-dependent cyto-
kines on these morphological features of a hypertrophic re-
sponse, cardiomyocytes were treated with CT-1, LIF, or CNTF
and dual-stained with an anti-TrpE/MLC-2v antiserum and a
monoclonal anti-ANF antibody. Unstimulated cells and PE-
treated cells served as negative and positive controls, respec-
tively. The effects of CT-1, LIF, CNTF, and PE on cardiomyo-
cyte area, length, and width and the percentage of cells
displaying perinuclear accumulation of ANF are summarized
in Table 1A. CT-1 and LIF induced a hypertrophic response, as
evidenced by increases in cardiomyocyte area and the percent-
age of cells with perinuclear accumulation of immunoreactive
ANF. As compared to PE stimulation, CT-1 and LIF had a more
pronounced effect on cardiomyocyte length but did not signifi-
cantly affect cardiomyocyte width. Treatment of cardiomyo-
cytes with CNTF did not induce significant morphology
changes as compared to control. Cardiomyocytes were dual-
stained with a monoclonal anti-bMHC antibody and rhodamine
phalloidine, to allow a simultaneous assessment of thick fila-
ment (bMHC) and thin filament (F-actin) assembly (56). Im-
ages were obtained by confocal laser microscopy. Representa-
tive high power fields are depicted in Fig. 5. Cardiomyocytes
stimulated with CT-1 (Panels E and F) and LIF (Panels G and
H) displayed a high degree of sarcomeric organization: myofi-
brils were oriented along the longitudinal cell axis, and ex-
tended into the tips of the cytoplasmic projections. As compared
with PE stimulation (Panels C and D), sarcomeric units were
assembled predominantly in series, rather than in parallel
(most striking in cytoplasmic projections containing only a few
myofibrils (see Panels E–H)). As shown in Table 1B, the aver-
age sarcomeric length did not differ significantly among the
experimental groups.
CT-1 Induces ANF Gene Expression—The reactivation of an
embryonic pattern of gene expression is a hallmark of cardio-
myocyte hypertrophy. We therefore determined whether stim-
ulation of cardiomyocytes with CT-1, LIF, or CNTF would
induce embryonic gene expression (Fig. 6). As shown previously
(11), stimulation of neonatal rat ventricular cardiomyocytes
with PE resulted in a significant (5.1-fold) increase in prepro-
ANF mRNA levels. Likewise, treatment with CT-1 or LIF stim-
ulated prepro-ANFmRNA expression (5.1- and 5.0-fold, respec-
tively). By contrast, CNTF did not significantly affect prepro-
ANF mRNA levels. As previously reported (8), PE stimulation
resulted in an increase (4.5-fold) in skeletal a-actin mRNA
expression. CT-1, LIF, and CNTF, however, did not signifi-
cantly affect skeletal a-actin steady state mRNA levels. Fi-
nally, we examined the effects of CT-1, LIF, CNTF, and PE on
the expression of MLC-2v, a constitutively expressed contract-
FIG. 4. Protein tyrosine phosphorylation. Neonatal rat ventricular cardiomyocytes were plated into 15-cm dishes and serum-starved for 18
h. Thereafter the cells were stimulated with sIL-6R, IL-6, IL-6 and sIL-6R combined, LIF, and CT-1 (10 nM each), or PE (100 mM) for 10 min at
37 °C. Cell lysates were immunoprecipitated with an anti-gp130 antibody, subjected to SDS-PAGE, and immunoblotting with an anti-phospho-
tyrosine antibody as outlined under “Experimental Procedures” (Panel A). In addition, cell lysates were directly subjected to SDS-PAGE and
immunoblotting with an anti-phosphotyrosine antibody (Panel B).
TABLE I
Morphometric analysis
Control PE CT-1 LIF CNTF
Cella
Area (mm2) 345 6 17 635 6 42* 543 6 17*,# 508 6 24*,# 305 6 14§
Length (mm) 38 6 1 56 6 3* 74 6 3*,§ 79 6 3*,§ 38 6 1§
Width (mm) 22 6 1 29 6 1* 23 6 1§ 23 6 1§ 21 6 1§
ANF positive (%) 6 51 32 26 6
Sarcomereb
Length (mm) 1.72 6 0.07 1.73 6 0.07 1.72 6 0.06 1.70 6 0.05 1.71 6 0.08
a Neonatal rat ventricular cardiomyocytes were plated into chamber slides and incubated with no additions (control), PE (100 mM), CT-1, LIF,
or CNTF (1 nM each). After 48 h, the cells were immunostained against MLC-2v and ANF. Cell area, length, and width were measured in 50–60
MLC-2v-positive cells from six randomly chosen high power fields per condition. Values are means 6 S.E.; * p , 0.0001 versus control; # p , 0.01
versus PE; § p , 0.0001 versus PE. In addition, 250 cells from each group were scored for MLC-2v and ANF expression, and the percentage of
MLC-2v positive cells that displayed perinuclear staining for immunoreactive ANF was calculated.
b Twenty sarcomere segments were measured in each of 8–10 randomly chosen cardiomyocytes stained against bMHC, and viewed by confocal
laser microscopy. Values are means 6 S.E.; p 5 not significant.
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FIG. 5. Sarcomeric organization.
Neonatal rat ventricular cardiomyocytes
were plated into chamber slides and incu-
bated for 48 h with no additions (Panels A
and B), 100 mM PE (Panels C and D), 1 nM
CT-1 (Panels E and F), 1 nM LIF (Panels G
and H), or 1 nM CNTF (Panels I and J).
Cells were dual-labeled with an anti-
bMHC antibody (Panels A, C, E, G, and I)
and rhodamine phalloidine (Panels B, D,
F, H, and J), and viewed by confocal laser
microscopy. The bar (Panel A) represents
10 mm.
Cardiotrophin-1 Activates Cardiac Muscle Cell Hypertrophy9540
 at A
STO
N
 U
N
IV
ERSITY
 on M
arch 20, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
ile protein gene. PE stimulation resulted in a marginal 1.5-fold
induction of MLC-2v mRNA levels. By contrast, CT-1, LIF, and
CNTF did not induce MLC-2v mRNA expression (data not
shown). We next determined whether the increase in prepro-
ANF mRNA expression in response to CT-1 and LIF is accom-
panied by an increase in secretion of immunoreactive ANF. As
noted in the initial study reporting the cloning of CT-1 (19),
CT-1 induced ANF release from cardiomyocytes in a dose-de-
pendent manner (Fig. 7). Likewise, LIF increased the secretion
of ANF; maximum ANF release was observed with CT-1 and
LIF concentrations of 0.1–10 nM. Consistent with the ANF
Northern blot results, stimulation with CNTF did not induce
ANF release at any of the concentrations tested (Fig. 7).
CT-1 Activates the Transcription of the ANF Gene—To deter-
mine whether the induction of ANF by CT-1 results from an
increased ANF gene transcription, we performed nuclear
run-on transcription assays. We compared the ANF gene tran-
scription rate during stimulation with CT-1 and PE. A typical
experiment is presented in Table II and Fig. 8. Cardiomyocyte
nuclei were isolated at various time points during stimulation
with CT-1 or PE. Unstimulated cells served as a control. CT-1
and PE increased the overall RNA transcription rate, as meas-
ured by the total amount of 32P incorporation into purified
run-on RNA (Table II). The overall RNA transcription rate was
higher at the early time points (0, 6, and 12 h), i.e. shortly after
serum withdrawal (Table II). An equal number of cpm from
each run-on reaction was hybridized to denatured prepro-ANF
and GAPDH cDNAs immobilized onto nylon filters. The ANF
autoradiograms are shown in Fig. 8A. The CT-1 and PE in-
duced ANF transcription rates were calculated as -fold induc-
tion over the corresponding control values from each time point
(Fig. 8B). ANF transcription reached a maximum 2.0-fold
(CT-1) and 2.1-fold (PE) increase versus control at 24 h and
returned to control levels at 48 h. By contrast, GAPDH gene
transcription was not affected by CT-1 or PE (not shown). The
FIG. 6. Expression of prepro-ANF and skeletal a-actin mRNAs.Neonatal rat ventricular cardiomyocytes were plated into 15-cm dishes and
incubated for 48 h with no additions (control), PE (100 mM), CT-1, LIF, or CNTF (1 nM each). Total RNA was isolated and subjected to Northern
blot analysis (10 mg/lane) using prepro-ANF and skeletal a-actin cDNA probes. Equal loading and transfer conditions were confirmed by GAPDH
and 28s hybridization. Representative blots are presented in Panel A. The results from three independent experiments, expressed as -fold induction
over control, are depicted in Panels B and C. Values are means 6 S.E.; *p , 0.05, **p , 0.01 versus control.
FIG. 7. Release of immunoreactive ANF from myocardial cells.
Neonatal rat ventricular cardiomyocytes were cultured in 24- well
plates, and stimulated for 48 h with various concentrations of CT-1,
LIF, and CNTF. ANF concentrations in the culture supernatants were
determined by radioimmunoassay. Values are means 6 S.E. from trip-
licate wells. Supernatants from unstimulated control cells and PE (100
mM) stimulated cells contained 2.5 6 0.4 nM and 20.8 6 1.5 nM ANF,
respectively. Two additional experiments yielded comparable results.
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CT-1- and PE-induced increase in ANF gene transcription was
accompanied by a time-dependent accumulation of prepro-ANF
mRNA in the cytosol, reaching maximum levels between 24
and 48 h (Fig. 8C). By contrast, CT-1 and PE did not affect
GAPDH mRNA expression (not shown).
CT-1 Responsive Cis-regulatory Sequences Are Located Out-
side a 3003-bp ANF Promoter Fragment—The transcriptional
up-regulation of the ANF gene in response to a number of
G-protein coupled receptor agonists, including PE, is mediated
by cis-regulatory elements, which are located within the prox-
imal 3 kb of ANF 59-flanking region (11, 12, 57). We performed
transient transfection analyses to determine whether gp130/
LIFRb-dependent cytokines and PE utilize common cis-acting
elements within the ANF promoter region. Cardiomyocytes
were transfected with an ANF-luciferase reporter construct
containing 3003 bp of the rat ANF 59-flanking region. Cardio-
myocytes transfected with a RSV-luciferase construct or a pro-
moterless luciferase construct were used as positive and nega-
tive controls, respectively. To control for transfection efficiency,
cells were cotransfected with a b-galactosidase expression vec-
tor. The cells were then stimulated with PE, CT-1, LIF, or
CNTF; unstimulated cells served as controls. At various time
points, cardiomyocytes were harvested for luciferase and b-ga-
lactosidase assays. As previously reported (11), the 3003-bp
ANF promoter fragment conferred PE-inducible expression to
the luciferase reporter gene (maximum 23.7-fold induction at
48 h) (Fig. 9). By contrast, the 3003-bp ANF promoter fragment
did not mediate inducible expression by CT-1, LIF, or CNTF
(Fig. 9). Luciferase activities in cells transfected with the RSV-
luciferase construct were on average 80-fold higher as com-
pared to unstimulated cells transfected with the ANF-lucifer-
ase construct and were not induced by any of the treatments
(not shown). Cells transfected with the promoterless reporter
construct displayed luciferase activities that were not different
from background values and were not affected by any of the
treatments (not shown). Considering that CT-1 as well as PE
increase the ANF gene transcription rate (as demonstrated by
nuclear run-on assays), the transfection analyses suggest that,
in contrast to PE, the CT-1 responsive cis-regulatory elements
are located outside of 3 kb of ANF 59-flanking region. Thus,
divergent pathways appear to mediate the induction of the
ANF gene in response to CT-1 as compared to a-adrenergic
stimulation.
DISCUSSION
CT-1 Signaling through the gp130/LIFRb Heterodimer—
Cardiotrophin-1 was recently isolated by expression cloning
based on its ability to induce an increase in cell size in car-
diomyocyte culture (19). The deduced amino acid sequence
suggested that CT-1 is a novel member of the IL-6, IL-11, LIF,
CNTF, and OSM family of structurally related cytokines, that
trigger downstream signaling pathways in multiple cell types
through the homodimerization of gp130 or the heterodimeriza-
tion of gp130 and LIFRb (22, 24, 26, 27). To determine whether
CT-1 shares the receptor components gp130 and/or LIFRb with
the other members of the IL-6 cytokine family, we employed a
FIG. 8. CT-1- and phenylephrine-in-
duced ANF gene transcription. Same
experiment as described in Table II. 1.2 3
106 cpm from each run-on reaction were
hybridized to linearized and denatured
pBluescript harboring the prepro-ANF
cDNA, immobolized onto nylon filters.
The filters were washed under stringent
conditions, and exposed to x-ray film for 5
days (Panel A). The signal intensities
were analyzed by densitometry to quanti-
tate the amount of ANF gene transcrip-
tion; data are presented as -fold induction
over control (Panel B). Total RNA was
isolated from the cytosolic fractions of the
same cells, that were used for the run-on
assays. RNA was subjected to Northern
blot analysis (7.5 mg/lane), using prepro-
ANF and 28s cDNA probes (Panel C).
Data from one experiment are presented.
One additional experiment yielded com-
parable results.
TABLE II
Total RNA transcription in control cells and CT-1- or phenylephrine-stimulated cells
Neonatal rat ventricular cardiomyocytes were plated into 15-cm dishes (10 3 106 cells/dish), allowed to attach overnight, and switched to
maintenance medium. Thereafter, nuclei from one dish were harvested (0 h, control). The remaining cells were further incubated with no additions
(controls), 1 nM CT-1, or 100 mM PE. Cardiomyocyte nuclei were isolated at the indicated time points, and nuclear run-on transcription assays were
performed as described under “Experimental Procedures.” The total amount of 32P incorporation into purified run-on RNA was determined by
liquid scintillation counting as an index of overall transcriptional activity. Data are presented as cpm 3 106.
Incubation
0 h 6 h 12 h 18 h 24 h 48 h
Control 5.2 2.9 2.4 1.7 1.3 1.4
CT-1 3.3 3.8 2.3 2.4 1.8
PE 5.3 3.7 1.9 1.8 1.4
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monoclonal anti-gp130 antibody and a mutated human LIF
protein, acting as a LIFRb antagonist. The c-fos induction by
CT-1 and LIF in cardiomyocytes was antagonized by the mono-
clonal anti-gp130 antibody as well as the LIFRb antagonist,
strongly suggesting that CT-1, like LIF, utilizes the receptor
components gp130 and LIFRb. As demonstrated by gp130 im-
munoprecipitation and subsequent anti-phosphotyrosine im-
munoblotting, stimulation of cardiomyocytes with CT-1, LIF,
and a combination of IL-6 and sIL-6R resulted in the rapid
tyrosine phosphorylation of gp130. These data indicate that
tyrosine phosphorylation of gp130 is an early step in CT-1
signaling, as it has previously been shown for the other mem-
bers of the IL-6 cytokine family (21–23). As determined by
immunoblotting with an anti-phosphotyrosine antibody, LIF
induced the tyrosine phosphorylation of an additional ;200
kDa protein, which was not phosphorylated upon stimulation
with the IL-6/sIL-6R complex. Based on previous results, this
protein most likely corresponds to LIFRb (22, 26, 58). Stimu-
lation of cardiac cells with CT-1 resulted in the tyrosine phos-
phorylation of a protein, indistinguishable in size from LIFRb,
as well. Considering the ability of the LIFRb antagonist to
block the action of CT-1 in cardiomyocytes, the immunoblotting
results strongly suggest that CT-1, like LIF, induces the tyro-
sine phosphorylation of LIFRb. In support of this conclusion,
CT-1 has recently been shown to bind to purified LIFRb in
solution with about the same affinity as LIF, and to interact
with a cell surface protein in M1 cells with a mobility expected
for LIFRb (54). In summary, the present study indicates that
CT-1 signals through and induces tyrosine phosphorylation of
the gp130/LIFRb heterodimer in cardiomyocytes.
CT-1 Induces a Hypertrophic Phenotype in Cultured Myocar-
dial Cells Characterized by Sarcomere Assembly in Series and
a Selective Up-regulation of ANF Gene Expression—The pres-
ent study provides clear evidence that the CT-1 induced hyper-
trophic phenotype is distinct from the hypertrophic phenotype
observed following G-protein-dependent stimulation. On a sin-
gle cell level, G-protein-dependent pathways induce a form of
hypertrophy with a relatively uniform increase in myocyte size
and the addition of new myofibrils in parallel (12, 15, 16). By
contrast, as noted in the present study, the gp130/LIFRb-de-
pendent cytokines CT-1 and LIF induce an increase in myocyte
size characterized by a marked increase in cell length, but little
or no change in cell width. To characterize the effects of gp130/
LIFRb-dependent stimulation on the myofibrillar cytoarchitec-
ture, cardiomyocytes were dual-stained against thick (bMHC)
and thin (F-actin) myofilaments, and viewed by confocal laser
microscopy (56). Cardiomyocytes stimulated with CT-1 and LIF
displayed a high degree of myofibrillar organization; myofibrils
were organized in a strictly sarcomeric pattern, were oriented
along the longitudinal cell axis, and extended to the cell pe-
riphery. Importantly, the increase in cell size and length was
associated with no change in the average sarcomere length,
strongly suggesting that the cell elongation in response to
gp130/LIFRb-dependent stimulation results from an addition
of new sarcomeric units in series. The morphologic changes
induced by gp130/LIFRb-dependent stimulation in vitro are
reminiscent of the changes observed in cardiac myocytes iso-
lated from hearts subjected to chronic volume overload (3, 4).
By contrast, the pattern of cardiomyocyte hypertrophy induced
by a-adrenergic stimulation more closely resembles a pressure
overload-like phenotype (1, 2).
On a molecular level, gp130/LIFRb-dependent stimulation
and a-adrenergic stimulation resulted in distinct patterns of
embryonic gene, MLC-2v, and immediate early gene expres-
sion. Stimulation of cardiomyocytes with CT-1 and LIF induced
prepro-ANF mRNA expression, and perinuclear accumulation
and secretion of immunoreactive ANF. However, in contrast to
a-adrenergic stimulation, CT-1 and LIF did not induce skeletal
a-actin expression. Growth factors, signaling through G-pro-
tein coupled receptors induce ANF and skeletal a-actin in a
coordinate fashion (8, 11–14). A recent study compared the
expression pattern of distinct members of the embryonic gene
program in pressure overload versus volume overload hyper-
trophy in vivo in the rat myocardium (5). As shown previously
(52), pressure overload resulted in the coordinate induction of
ANF and skeletal a-actin. However, volume overload hypertro-
phy was associated with a selective increase in ANF expres-
sion, and no induction of skeletal a-actin, suggesting that the
regulation of distinct embryonic genes in vivo is related to the
hypertrophic stimulus (5). The pattern of embryonic gene ex-
pression induced by CT-1 and LIF in cardiomyocyte culture
therefore resembles the pattern observed in volume overload
hypertrophy in vivo.
Nuclear run-on transcription assays revealed that the induc-
tion of prepro-ANF mRNA by CT-1 and a-adrenergic stimula-
tion is mediated, at least in part, by an increased transcription
of the ANF gene. The fact that the ANF mRNA levels increased
5-fold, whereas the ANF gene transcription rate increased only
2-fold, suggests that post-transcriptional mechanisms(s) par-
ticipate in the up-regulation of ANF gene expression in re-
sponse to CT-1 and PE (59). In agreement with previous results
(11), a 3003-bp ANF promoter fragment conferred PE-inducible
expression to a luciferase reporter gene. Likewise, the cis-
regulatory elements mediating ANF inducibility in response to
endothelin 1 and a-thrombin reside within the proximal 3 kb of
the ANF 59-flanking region, suggesting that G-protein-coupled
receptor agonists may utilize common signaling pathways for
the induction of ANF (12, 57). By contrast, none of the gp130/
LIFRb-dependent cytokines (CT-1, LIF, and CNTF) activated
the 3003-bp ANF promoter fragment. Considering the in-
creased ANF gene transcription rate in response to CT-1 and
PE, we conclude that in contrast to a-adrenergic stimulation,
the CT-1 responsive cis-regulatory elements are located outside
of the proximal 3 kb of the ANF 59-flanking region. In recent
studies, transgenic mice harboring 3003 bp of ANF 59-flanking
region upstream of a luciferase reporter gene were subjected to
FIG. 9. Transient transfection analysis of a 3003- bp ANF pro-
moter-luciferase reporter construct. Neonatal rat ventricular car-
diomyocytes were cotransfected with an ANF-luciferase reporter con-
struct (pANF(23003)Luc59) and a b-galactosidase control vector
(pON249), and incubated with no additions (control), PE (100 mM),
CT-1, LIF, or CNTF (1 nM each). At the indicated time points, cells were
harvested for luciferase and b-galactosidase assays. Luciferase activi-
ties were normalized to b-galactosidase activities. Results are pre-
sented as -fold induction over control cells harvested at corresponding
time points. Values are means 6 S.E. of four experiments at each time
point; *p , 0.01 versus control.
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transverse aortic banding. Despite a marked increase in left
ventricular prepro-ANF mRNA expression, no significant in-
crease in reporter activity was observed (60). These findings
demonstrate that the induction of ANF during cardiac hyper-
trophy in vivo occurs through a distinct mechanism as com-
pared to G-protein-mediated cardiomyocyte hypertrophy in
vitro. Unraveling the mechanisms of ANF induction in re-
sponse to gp130/LIFRb-dependent stimulation may therefore
provide insight into the mechanisms governing the induction of
ANF during in vivo cardiac hypertrophy.
CT-1 and LIF did not induce MLC-2v mRNA expression,
whereas phenylephrine stimulation resulted in a marginal in-
duction of MLC-2v. The induction of MLC-2v on the mRNA
level may be a feature unique to G-protein-coupled receptor
stimulation of cardiomyocytes in vitro (10, 12): MLC-2v mRNA
expression is not up-regulated in the hypertrophic right ven-
tricles of pulmonary artery-banded mice (61) and in the hyper-
trophic ventricles of transgenic mice overexpressing a consti-
tutively active a-adrenergic receptor in the myocardium (62).
A distinct response to gp130/LIFRb-dependent versus a-ad-
renergic stimulation was also observed at the level of immedi-
ate early gene induction. As compared to a-adrenergic stimu-
lation, CT-1 and LIF induced .10-fold higher levels of c-myc
and tis11 expression. Immediate early genes encode known or
putative transcription factors, and potential binding sites have
been identified in the promoter regions of a number of cardiac
genes (for review, see Ref. 63). The distinct combinatorial ex-
pression of immediate early genes may therefore relate to the
differences in cell morphology and gene expression pattern in
response to gp130/LIFRb-dependent versus a-adrenergic
stimulation.
Taken together, these studies indicate that gp130/LIFRb-de-
pendent pathways can activate a hypertrophic phenotype in
cardiac muscle cells which is distinct both at a morphological
and a molecular level from the phenotype seen following G-
protein-dependent stimulation, and that is more consistent
with a volume overload, as opposed to pressure overload, hy-
pertrophic phenotype. Future studies in transgenic mice will be
required to rigorously test whether gp130/LIFRb-dependent
signaling pathways are implicated in volume overload and/or
pressure overload ventricular hypertrophy in vivo, in a manner
analogous to recent studies exploring the in vivo role of ras-de-
pendent pathways (18). In this regard, double transgenic mice
overexpressing IL-6 and IL-6R have recently been generated
(64). These mice display a constitutive tyrosine phosphoryla-
tion (i.e. activation) of gp130 in the myocardium and left ven-
tricular hypertrophy with increases in cardiac weights and
cardiomyocyte volumes. These results suggest that the induc-
tion of cardiomyocyte hypertrophy through gp130-dependent
signaling pathways is not confined to the in vitro hypertrophy
assay, but may also be observed in the in vivo context.
The question arises as to the relative role of individual mem-
bers of the IL-6 cytokine family in the activation of a hyper-
trophic response in vivo. The expression of IL-6R in the heart of
wild type mice is extremely low, making IL-6 an unlikely me-
diator of cardiac hypertrophy in vivo.4 Accordingly, a combina-
tion of IL-6 with sIL-6R was required to induce tyrosine phos-
phorylation of gp130 in cardiomyocytes in the present study.
Likewise, the myocardium does not express substantial levels
of CNTFRa (30), and cardiomyocytes did not respond to CNTF
stimulation in the present study. It should be noted, however,
that CNTF exerted marginal effects on immediate early gene
expression in cardiomyocytes. This might relate to a weak
interaction of CNTF with the gp130/LIFRb heterodimer in the
absence of CNTFRa (65, 66). Alternatively, low level expression
of CNTFRa in cardiomyocytes may account for a weak respon-
siveness to CNTF. The CT-1 mRNA is expressed in the heart
from adult mice (19). RNase protection analysis of cardiac
muscle cells and cardiac-derived fibroblasts from neonatal rats
reveals a .10-fold higher level of CT-1 mRNA expression in
cardiac muscle cells versus cardiac fibroblasts, and CT-1 is
expressed primarily in cardiac muscle cells during murine car-
diogenesis (67). By contrast, the expression of LIF mRNA in the
adult murine heart is extremely low as documented by RNase
protection analysis (68, 69). These data would suggest that
CT-1 is a candidate cytokine activating gp130/LIFRb-depend-
ent signaling pathways within the myocardium, potentially
through an autocrine pathway. The generation of mice contain-
ing a null-mutation of the CT-1 gene should provide a more
definitive understanding of the in vivo role of CT-1 in develop-
ment and in cardiac hypertrophy in the adult animal.
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